1-(4-methoxythiophen-2-yl)ethan-1-one

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1-(4-methoxythiophen-2-yl)ethan-1-one
• 英文别名: 1-(4-Methoxythiophen-2-yl)ethan-1-one；1-(4-methoxythiophen-2-yl)ethanone
• 化学式: C₇H₈O₂S
• 分子量: 156.205
• InChiKey: MGUUJAIXQQGGAF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  54.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-(4-methoxythiophen-2-yl)ethan-1-one 、 1-(4-异硫代氰酰基苯基)-4-甲基哌嗪 在 sodium hydride 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 反应 7.0h， 生成
  参考文献：
  名称：

  Combining structure- and property-based optimization to identify selective FLT3-ITD inhibitors with good antitumor efficacy in AML cell inoculated mouse xenograft model

  摘要：

  FLT3 mutation is among the most common genetic mutations in acute myeloid leukemia (AML), which is also related with poor overall survival and refractory in AML patients. Recently, FLT3 inhibitors have been approved for AML therapy. Herein, a series of new compounds with pyrazole amine scaffold was discovered, which showed potent inhibitory activity against FLT3-ITD and significant selectivity against both FLT3-ITD and AML cells expressing FLT3-ITD. Compound 46, possessing the most promising cellular activity, blocked the autophosphorylation of FLT3 pathway in MV4-11 cell line. Furthermore, the apoptosis and downregulation of P-STAT5 were also observed in tumor cells extracted from the MV411 cell xenografts model upon compound 46 treatment. Compound 46 was also metabolically stable in vitro and suppressed tumor growth significantly in MV4-11 xenografts model in vivo. Compound 46 showed no toxicity to the viscera of mice and caused no decrease in body weight of mice. In conclusion, the results of this study could provide valuable insights into discovery of new FLT3 inhibitors, and compound 46 was worthy of further development as potential drug candidate to treat AML (C) 2019 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2019.05.021
• 作为产物：
  描述：

  4-溴-2-乙酰基噻吩 、 sodium methylate 在 copper(I) bromide 作用下， 以 甲醇 为溶剂， 反应 16.0h， 以31%的产率得到1-(4-methoxythiophen-2-yl)ethan-1-one
  参考文献：
  名称：

  HETEROCYCLIC INHIBITORS OF MCT4

  摘要：

  本文披露了一些化合物和组合物，适用于治疗由MCT4介导的疾病，如增殖性和炎症性疾病，其结构如下所示： 还提供了在人类或动物主体中抑制MCT4活性的方法。

  公开号：

  US20180162822A1

文献信息

• [EN] MCT4 INHIBITORS FOR TREATING DISEASE<br/>[FR] INHIBITEURS DE MCT4 POUR LE TRAITEMENT DE MALADIES
  申请人：VETTORE LLC

  公开号：WO2016201426A1

  公开（公告）日：2016-12-15

  Disclosed herein are compounds and compositions useful in the treatment of MCT4 mediated diseases, such as proliferative and inflammatory diseases, having the structure of Formula I: Methods of inhibition MCT4 activity in a human or animal subject are also provided.

  本文披露了一种在治疗MCT4介导的疾病中有用的化合物和组合物，如增殖性和炎症性疾病，其具有Formula I的结构：还提供了在人类或动物主体中抑制MCT4活性的方法。
• MCT4 inhibitors for treating disease
  申请人：Vettore, LLC

  公开号：US10202350B2

  公开（公告）日：2019-02-12

  Disclosed herein are compounds and compositions useful in the treatment of MCT4 mediated diseases, such as proliferative and inflammatory diseases, having the structure of Formula I: Methods of inhibition MCT4 activity in a human or animal subject are also provided.

  本文公开了用于治疗 MCT4 介导的疾病（如增殖性和炎症性疾病）的化合物和组合物，其结构如式 I 所示： 还提供了抑制人或动物体内 MCT4 活性的方法。
• MCT4 INHIBITORS FOR TREATING DISEASE
  申请人：Vettore, LLC

  公开号：EP3307068A1

  公开（公告）日：2018-04-18
• [EN] HETEROCYCLIC INHIBITORS OF MCT4<br/>[FR] INHIBITEURS HÉTÉROCYCLIQUES DE MCT4
  申请人：VETTORE LLC

  公开号：WO2018111904A1

  公开（公告）日：2018-06-21

  Disclosed herein are compounds and compositions useful in the treatment of MCT4 mediated diseases, such as proliferative and inflammatory diseases, having the structure of Formula (I). Methods of inhibition MCT4 activity in a human or animal subject are also provided.
• HETEROCYCLIC INHIBITORS OF MCT4
  申请人：Vettore, LLC

  公开号：US20180162822A1

  公开（公告）日：2018-06-14

  Disclosed herein are compounds and compositions useful in the treatment of MCT4 mediated diseases, such as proliferative and inflammatory diseases, having the structure of Formula I: Methods of inhibition MCT4 activity in a human or animal subject are also provided.

  本文披露了一些化合物和组合物，适用于治疗由MCT4介导的疾病，如增殖性和炎症性疾病，其结构如下所示： 还提供了在人类或动物主体中抑制MCT4活性的方法。